{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Hyangsayukgunja-tang", "drug-drug interaction", "erlotinib", "gemcitabine", "herbal medicine", "pharmacokinetics", "population pharmacokinetic modeling"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28891960", "DateCompleted": {"Year": "2018", "Month": "05", "Day": "15"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "09", "Day": "10"}], "Language": ["eng"], "ELocationID": ["1515", "10.3390/molecules22091515"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "22", "Issue": "9", "PubDate": {"Year": "2017", "Month": "Sep", "Day": "10"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.", "Abstract": {"AbstractText": ["Gemcitabine and erlotinib are the chemotherapeutic agents used in the treatment of various cancers and their combination is being accepted as a first-line treatment of advanced pancreatic cancer. Hyangsayukgunja-tang (HYT) is a traditional oriental medicine used in various digestive disorders and potentially helpful to treat gastrointestinal adverse effects related to chemotherapy. The present study was aimed to evaluate the effect of HYT on the pharmacokinetics of gemcitabine and erlotinib given simultaneously in rats. Rats were pretreated with HYT at an oral dose of 1200 mg/kg/day once daily for a single day or 14 consecutive days. Immediately after pretreatment with HYT, gemcitabine and erlotinib were administered by intravenous injection (10 mg/kg) and oral administration (20 mg/kg), respectively. The effects of HYT on pharmacokinetics of the two drugs were estimated by non-compartmental analysis and pharmacokinetic modeling. The pharmacokinetics of gemcitabine and erlotinib were not altered by single dose HYT pretreatment. However, the plasma levels of OSI-420 and OSI-413, active metabolites of erlotinib, were significantly decreased in the multiple dose HYT pretreatment group. The pharmacokinetic model estimated increased systemic clearances of OSI-420 and OSI-413 by multiple doses of HYT. These data suggest that HYT may affect the elimination of OSI-420 and OSI-413."]}, "AuthorList": [{"Identifier": ["0000-0003-1234-1681"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA. taehwan.kim@cop.ufl.edu."}], "LastName": "Kim", "ForeName": "Tae Hwan", "Initials": "TH"}, {"Identifier": ["0000-0001-8328-1087"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Wonkwang University, Iksan, Jeonbuk 54538, Korea. shins@wku.ac.kr."}], "LastName": "Shin", "ForeName": "Soyoung", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA. sarahkim@cop.ufl.edu."}], "LastName": "Kim", "ForeName": "Sarah", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA. JBulitta@cop.ufl.edu."}], "LastName": "Bulitta", "ForeName": "J\u00fcrgen B", "Initials": "JB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Catholic University of Daegu, 13-13 Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongbuk 38430, Korea. weonky@cu.ac.kr."}], "LastName": "Weon", "ForeName": "Kwon-Yeon", "Initials": "KY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Catholic University of Daegu, 13-13 Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongbuk 38430, Korea. sjoo@cu.ac.kr."}], "LastName": "Joo", "ForeName": "Sang Hoon", "Initials": "SH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Catholic University of Daegu, 13-13 Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongbuk 38430, Korea. masook@cu.ac.kr."}], "LastName": "Ma", "ForeName": "Eunsook", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Korea. sdyoo@skku.ac.kr."}], "LastName": "Yoo", "ForeName": "Sun Dong", "Initials": "SD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rehabilitation Medicine, School of Medicine, Catholic University of Daegu, Daegu 42472, Korea. parkgy@cu.ac.kr."}], "LastName": "Park", "ForeName": "Gi-Young", "Initials": "GY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rehabilitation Medicine, School of Medicine, Catholic University of Daegu, Daegu 42472, Korea. coolkwon@cu.ac.kr."}], "LastName": "Kwon", "ForeName": "Dong Rak", "Initials": "DR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Catholic University of Daegu, 13-13 Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongbuk 38430, Korea. jswpia@gmail.com."}], "LastName": "Jeong", "ForeName": "Seok Won", "Initials": "SW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Catholic University of Daegu, 13-13 Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongbuk 38430, Korea. dayoung0717@gmail.com."}], "LastName": "Lee", "ForeName": "Da Young", "Initials": "DY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Korea. bsshin@skku.edu."}], "LastName": "Shin", "ForeName": "Beom Soo", "Initials": "BS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "OSI-420"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Protective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "0W860991D6", "NameOfSubstance": "Deoxycytidine"}, {"RegistryNumber": "DA87705X9K", "NameOfSubstance": "Erlotinib Hydrochloride"}, {"RegistryNumber": "0", "NameOfSubstance": "Gemcitabine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": [], "DescriptorName": "Area Under Curve"}, {"QualifierName": [], "DescriptorName": "Biological Availability"}, {"QualifierName": [], "DescriptorName": "Biotransformation"}, {"QualifierName": ["analogs & derivatives", "blood", "pharmacokinetics"], "DescriptorName": "Deoxycytidine"}, {"QualifierName": [], "DescriptorName": "Drug Administration Schedule"}, {"QualifierName": [], "DescriptorName": "Drug Interactions"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Erlotinib Hydrochloride"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["metabolism", "pharmacokinetics"], "DescriptorName": "Protective Agents"}, {"QualifierName": ["blood"], "DescriptorName": "Quinazolines"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Gemcitabine"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., Zaniboni A., Ducreux M., Aitini E., Taieb J., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a gercor and giscad phase III trial. J. Clin. Oncol. 2005;23:3509\u20133516. doi: 10.1200/JCO.2005.06.023.", "ArticleIdList": ["10.1200/JCO.2005.06.023", "15908661"]}, {"Citation": "Oberstein P.E., Olive K.P. Pancreatic cancer: Why is it so hard to treat? Ther. Adv. Gastroenterol. 2013;6:321\u2013337. doi: 10.1177/1756283X13478680.", "ArticleIdList": ["10.1177/1756283X13478680", "PMC3667471", "23814611"]}, {"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017;67:7\u201330. doi: 10.3322/caac.21387.", "ArticleIdList": ["10.3322/caac.21387", "28055103"]}, {"Citation": "Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913\u20132921. doi: 10.1158/0008-5472.CAN-14-0155.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-0155", "24840647"]}, {"Citation": "Burris H.A., \u0406\u0406\u0406, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997;15:2403\u20132413. doi: 10.1200/JCO.1997.15.6.2403.", "ArticleIdList": ["10.1200/JCO.1997.15.6.2403", "9196156"]}, {"Citation": "Hochster H.S., Haller D.G., de Gramont A., Berlin J.D., Philip P.A., Moore M.J., Ajani J.A. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676\u2013685. doi: 10.1002/cncr.22036.", "ArticleIdList": ["10.1002/cncr.22036", "16847885"]}, {"Citation": "Bria E., Milella M., Gelibter A., Cuppone F., Pino M.S., Ruggeri E.M., Carlini P., Nistico C., Terzoli E., Cognetti F., et al. Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer. 2007;110:525\u2013533. doi: 10.1002/cncr.22809.", "ArticleIdList": ["10.1002/cncr.22809", "17577216"]}, {"Citation": "Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group. J. Clin. Oncol. 2007;25:1960\u20131966. doi: 10.1200/JCO.2006.07.9525.", "ArticleIdList": ["10.1200/JCO.2006.07.9525", "17452677"]}, {"Citation": "Sun C., Ansari D., Andersson R., Wu D.Q. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J. Gastroenterol. 2012;18:4944\u20134958. doi: 10.3748/wjg.v18.i35.4944.", "ArticleIdList": ["10.3748/wjg.v18.i35.4944", "PMC3447278", "23002368"]}, {"Citation": "Shin S., Park C.M., Kwon H., Lee K.H. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: Real-world analysis of korean national database. BMC Cancer. 2016;16:443. doi: 10.1186/s12885-016-2482-z.", "ArticleIdList": ["10.1186/s12885-016-2482-z", "PMC4940912", "27400734"]}, {"Citation": "Yang Z.Y., Yuan J.Q., Di M.Y., Zheng D.Y., Chen J.Z., Ding H., Wu X.Y., Huang Y.F., Mao C., Tang J.L. Gemcitabine plus erlotinib for advanced pancreatic cancer: A systematic review with meta-analysis. PLoS ONE. 2013;8:e57528. doi: 10.1371/journal.pone.0057528.", "ArticleIdList": ["10.1371/journal.pone.0057528", "PMC3589410", "23472089"]}, {"Citation": "European Medicines Agency (EMA) Assessment Report for Tarceva. EMA; London, UK: 2010."}, {"Citation": "Hamilton M., Wolf J.L., Zborowski D., Lu J., Lum B.L., Ding K., Clark G.M., Rakhit A., Seymour L., Ptaszynski A.M., et al. Tarceva\u2122 (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced nsclc: Effect of smoking on the pk of erlotinib. Cancer Res. 2005;65:1451."}, {"Citation": "Iyer R., Bharthuar A. A review of erlotinib\u2014An oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin. Pharmacother. 2010;11:311\u2013320. doi: 10.1517/14656560903551283.", "ArticleIdList": ["10.1517/14656560903551283", "20088749"]}, {"Citation": "U.S. FDA . FDA Approval for Erlotinib Hydrochloride. FDA; Silver Spring, MD, USA: 2013."}, {"Citation": "Bent S. Herbal medicine in the united states: Review of efficacy, safety, and regulation: Grand rounds at university of California, San Francisco medical center. J. Gen. Intern. Med. 2008;23:854\u2013859. doi: 10.1007/s11606-008-0632-y.", "ArticleIdList": ["10.1007/s11606-008-0632-y", "PMC2517879", "18415652"]}, {"Citation": "Brantley S.J., Argikar A.A., Lin Y.S., Nagar S., Paine M.F. Herb-drug interactions: Challenges and opportunities for improved predictions. Drug Metab. Dispos. 2014;42:301\u2013317. doi: 10.1124/dmd.113.055236.", "ArticleIdList": ["10.1124/dmd.113.055236", "PMC3935140", "24335390"]}, {"Citation": "Meng Q., Liu K. Pharmacokinetic interactions between herbal medicines and prescribed drugs: Focus on drug metabolic enzymes and transporters. Curr. Drug Metab. 2014;15:791\u2013807. doi: 10.2174/1389200216666150223152348.", "ArticleIdList": ["10.2174/1389200216666150223152348", "25705905"]}, {"Citation": "Seo C.S., Shin H.K. Quantitative analysis of Hyangsayukgunja-tang using an ultra-performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry. Korean J. Pharmacogn. 2015;46:352\u2013364."}, {"Citation": "Oriental Medicine Advanced Searching Integrated System (OASIS): Hyangsayukgunja-Tang.  [(accessed on 28 August 2017)]; Available online:  http://oasis.kiom.re.kr/oasis/pres/prdetailView2.jsp?idx=31&selectname=%ED%96%A5%EC%82%AC%EC%9C%A1%EA%B5%B0%EC%9E%90%ED%83%95&srch_menu_nix=null."}, {"Citation": "Kong K.H., Baik T.H. The effects of Hyangsayukgunja-tang extract on indomethacin-induced gatric mucosal lesions. J. Intern. Korean Med. 2001;22:589\u2013599."}, {"Citation": "Chang H.Y., Kang Y.H. The effects of hyang-sa-yuk-gun-ja-tang and oh-pe-san on the gastric mucosal repair. J. Dong Guk Orient. Med. 1993;2:127\u2013137."}, {"Citation": "Jeong Y. Hyangsayukgunja-Tang Increases Appetite and Affects Gut Hormones. Kyung-Hee University; Seoul, Korea: 2011."}, {"Citation": "Li X. Study on anti-inflammation and analgesia of Xiangshaliujun granule. J. Luzhou Med. Coll. 2005;28:409\u2013411."}, {"Citation": "Xiao Y., Liu Y.Y., Yu K.Q., Ouyang M.Z., Luo R., Zhao X.S. Chinese herbal medicine liu jun zi tang and xiang sha liu jun zi tang for functional dyspepsia: Meta-analysis of randomized controlled trials. Evid. Based Complement. Alternat. Med. 2012;2012:936459. doi: 10.1155/2012/936459.", "ArticleIdList": ["10.1155/2012/936459", "PMC3530827", "23304226"]}, {"Citation": "Zhang Y., Zheng T., Li W. Effects of xiang sha liu jun zi tang and its component on contractile activity of isolated gastric muscle strips in rats. J. Lanzhou Med. Coll. 1999;25:1\u20133."}, {"Citation": "Jeong M.J., Lyu S.A., Lee S.Y. Effects of the hyangsayukgunjatang gamibang on children with abdominal pain. J. Korean Orient. Pediatr. 2007;21:57\u201369."}, {"Citation": "Ye H.M., Lin N., Xiao L.Y. Antioxidant activity of xiangsha liujun pill in hyperlipidemia model rats. China Pharm. 2008;24:013."}, {"Citation": "Gemzar\u00ae (Gemcitabine HCL)  [(accessed on 28 August 2017)]; Available online:  https://pi.lilly.com/us/gemzar.pdf."}, {"Citation": "Kim T.H., Park G.Y., Shin S., Kwon D.R., Seo W.S., Shin J.C., Choi J.H., Joo S.H., Weon K.Y., Min B.S., et al. Pharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in rats. Evid. Based Complement. Alternat. Med. 2014;2014:402126. doi: 10.1155/2014/402126.", "ArticleIdList": ["10.1155/2014/402126", "PMC4229966", "25530781"]}, {"Citation": "Oga E.F., Sekine S., Shitara Y., Horie T. Pharmacokinetic herb-drug interactions: Insight into mechanisms and consequences. Eur. J. Drug Metab. Pharmacokinet. 2016;41:93\u2013108. doi: 10.1007/s13318-015-0296-z.", "ArticleIdList": ["10.1007/s13318-015-0296-z", "26311243"]}, {"Citation": "Ting C.T., Cheng Y.Y., Tsai T.H. Herb-drug interaction between the traditional hepatoprotective formulation and sorafenib on hepatotoxicity, histopathology and pharmacokinetics in rats. Molecules. 2017;22:1034. doi: 10.3390/molecules22071034.", "ArticleIdList": ["10.3390/molecules22071034", "PMC6152211", "28640225"]}, {"Citation": "Clinical Research Information Service.  [(accessed on 28 August 2017)]; Available online:  https://cris.nih.go.kr/cris/search/search_result_st01.jsp?seq=4708."}, {"Citation": "Signor L., Varesio E., Staack R.F., Starke V., Richter W.F., Hopfgartner G. Analysis of erlotinib and its metabolites in rat tissue sections by maldi quadrupole time-of-flight mass spectrometry. J. Mass Spectrom. 2007;42:900\u2013909. doi: 10.1002/jms.1225.", "ArticleIdList": ["10.1002/jms.1225", "17534860"]}, {"Citation": "Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., Cagnoni P.J. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 2006;12:2166\u20132171. doi: 10.1158/1078-0432.CCR-05-2235.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-2235", "16609030"]}, {"Citation": "Kim K.S., Shin H.M. Antioxidant effects of gami hyang sa yuk gun ja tang against gastric mucosal lesions iduced by indomethacin. J. Korean Med. 1998;19:165\u2013178."}]}], "History": [{"Year": "2017", "Month": "7", "Day": "10"}, {"Year": "2017", "Month": "9", "Day": "1"}, {"Year": "2017", "Month": "9", "Day": "8"}, {"Year": "2017", "Month": "9", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "9", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "9", "Day": "10"}], "PublicationStatus": "epublish", "ArticleIdList": ["28891960", "PMC6151743", "10.3390/molecules22091515", "molecules22091515"]}}]}